James B. Breitmeyer

Insider Reports History

SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Edward Berg, attorney-in-fact for James B. Breitmeyer
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for James B. Breitmeyer

Form 4 holding Chief Executive Officer, Director

Oncternal Therapeutics, Inc.

Security class
Common Stock
Shares / value
443,034
Estimated value
$219,789
Report date
03 Jan 2024
Price
$0.4961
Ownership
Direct
Form 4 holding Chief Executive Officer, Director

Oncternal Therapeutics, Inc.

Security class
Common Stock
Shares / value
196,544
Estimated value
$97,505
Report date
03 Jan 2024
Price
$0.4961
Ownership
By Family Trust
Form 4 holding Chief Executive Officer, Director

Oncternal Therapeutics, Inc.

Security class
Common Stock
Shares / value
15,426
Estimated value
$7,653
Report date
03 Jan 2024
Price
$0.4961
Ownership
By Spouse
Form 4 holding Chief Executive Officer, Director

Oncternal Therapeutics, Inc.

Security class
Common Stock
Shares / value
733
Estimated value
$364
Report date
03 Jan 2024
Price
$0.4961
Ownership
By Child
Form 4 holding Director

Vaxart, Inc.

Security class
Stock Option (right to buy)
Shares / value
157,400
Estimated value
Report date
23 Apr 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chief Executive Officer, Director

Oncternal Therapeutics, Inc.

Security class
Stock Option
Shares / value
28,400
Estimated value
Report date
14 Feb 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

OTONOMY, INC.

Security class
Stock Option (right to buy)
Shares / value
27,500
Estimated value
Report date
21 Jun 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chief Executive Officer, Director

Oncternal Therapeutics, Inc.

Security class
Stock Option
Shares / value
6,200
Estimated value
Report date
14 Feb 2024
Price
Ownership
By Spouse
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

ZOGENIX, INC.

Security class
Common Stock
Shares / value
0
Estimated value
Report date
07 Mar 2022
Price
$26.04
Ownership
Direct
Form 4 holding Director

ZOGENIX, INC.

Security class
Stock Option (Right to Buy)
Shares / value
0
Estimated value
Report date
07 Mar 2022
Price
$26.09
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by James B. Breitmeyer

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .